Search results for "Transplant Recipient"

showing 9 items of 49 documents

Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations.

2016

Cytomegalovirus (CMV) infection remains a major complication of solid organ transplantation. Because of management of CMV is variable among transplant centers, in 2011 the Spanish Transplantation Infection Study Group (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) developed consensus guidelines for the prevention and treatment of CMV infection in solid organ transplant recipients. Since then, new publications have clarified or questioned the aspects covered in the previous document. For that reason, a panel of experts revised the evidence on CMV management, including immunological monitoring, diagnostics, prevention, vaccines, indirect effects, tre…

medicine.medical_specialtyCongenital cytomegalovirus infectionMEDLINEDrug resistance030230 surgeryAntiviral AgentsOrgan transplantation03 medical and health sciences0302 clinical medicineMonitoring ImmunologicMedicineHumansMajor complicationIntensive care medicineTransplantationbusiness.industryOrgan Transplantationmedicine.diseaseTransplant RecipientsCytomegalovirus infectionClinical microbiologyImmunologyCytomegalovirus InfectionsPractice Guidelines as Topic030211 gastroenterology & hepatologybusinessSolid organ transplantationTransplantation reviews (Orlando, Fla.)
researchProduct

Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients.

2021

Diabetes is common in patients wait-listed for liver transplantation due to end-stage liver disease or to hepatocellular cancer as well as in post-transplant phase (post-transplantation diabetes mellitus-PTDM). In both conditions the presence of diabetes severely affects disease burden and long-term clinical outcomes; careful monitoring and appropriate treatment are pivotal to reduce cardiovascular events and graft and recipients' death. We thoroughly reviewed the epidemiology of diabetes in the transplant setting and the different therapeutic options, from lifestyle intervention to antidiabetic drug use - including the most recent drug classes available - and to the inclusion of bariatric …

medicine.medical_specialtyGLP-1 receptor agonistmedicine.medical_treatmentposttransplantation diabetes mellituDiseaseHypoglycemiaLiver transplantationLiver diseaseDiabetes mellitusmedicineDiabetes MellitusDPP-4 inhibitorHumansHypoglycemic AgentsIntensive care medicineDisease burdenTransplantationbusiness.industrySGLT-2 inhibitorsFatty livermedicine.diseaseDiabetes NAFLD Liver transplantationHypoglycemiaTransplant RecipientsLiver TransplantationTransplantationbusinessTransplantation
researchProduct

Impact of donor-recipient age on cardiac transplant survival. Subanalysis of the Spanish Heart Transplant Registry.

2020

[Abstract] Introduction and objectives. The age of heart transplant recipients and donors is progressively increasing. It is likely that not all donor-recipient age combinations have the same impact on mortality. The objective of this work was to compare survival in transplant recipients according to donor-recipient age combinations. Methods. We performed a retrospective analysis of transplants performed between 1 January 1993 and 31 December 2017 in the Spanish Heart Transplant Registry. Pediatric transplants, retransplants and combined transplants were excluded (6505 transplants included). Four groups were considered: a) donor < 50 years for recipient < 65 years; b) donor < 50 years for r…

medicine.medical_specialtyPrognostic factorTrasplante cardiacoMultivariate analysisSurvivalCombinaciones de edad de donante y receptor Donor age Donor/recipient age combinations Edad del donante Edad del receptor Heart transplant Recipient age Supervivencia Survival Trasplante cardiacoEnfermedad cardiovascularDonor/recipient age combinationsRecipient age030204 cardiovascular system & hematologyDonor age03 medical and health sciences0302 clinical medicineInternal medicineRetrospective analysisEdad del receptorMedicineHumansTrasplante de corazónRegistriesChildRetrospective StudiesSupervivenciabusiness.industryEdad del donanteGraft SurvivalAge FactorsCombinaciones de edad de donante y receptorGeneral MedicineTissue DonorsTransplant RecipientsTrasplante de órganosDatos estadísticosHeart TransplantationHeart transplantSupervivencia tisularbusinessMedian survival
researchProduct

CT evaluation of the renal donor and recipient

2018

Proper pre- and post-transplant diagnostic imaging work-up is fundamental in ensuring a successful outcome for renal transplantation. Despite exposure to ionizing radiation, CT has high spatial resolution and is a widely available and fast imaging technique. CT is performed routinely to delineate the anatomy of the kidney, relevant vasculature, and urinary collecting system in the living donor, to assess the iliac vessels in potential recipients prior to surgery, and to assess early and late-term post-transplant complications. The purpose of this article is to outline the optimal CT protocol and the main reportable findings for both the donor and the recipient diagnostic imaging work-up as …

medicine.medical_specialtyRadiology Nuclear Medicine and ImagingUrinary systemUrologyContrast Mediakidney transplantationliving donorcomplication030230 surgeryKidney030218 nuclear medicine & medical imaging03 medical and health sciencesPostoperative Complications0302 clinical medicinetransplant recipientInternal medicinePreoperative CareLiving DonorsmedicineHigh spatial resolutionMedical imagingHumansComputed tomographyKidney transplantationKidneyRadiological and Ultrasound Technologybusiness.industryGastroenterologyRadiation ExposureHepatologymedicine.diseaseTransplantationContrast mediummedicine.anatomical_structureRadiologyTomography X-Ray Computedbusiness
researchProduct

AISF position paper on HCV in immunocompromised patients.

2018

Abstract This report summarizes the clinical features and the indications for treating HCV infection in immunocompromised and transplanted patients in the Direct Acting Antiviral drugs era.

medicine.medical_specialtyTransplant RecipientComorbidityAntiviral AgentsOrgan transplantation03 medical and health sciencesImmunocompromised Host0302 clinical medicineInternal medicineNeoplasmsmedicineImmunocompromised patientHumansChronicIntensive care medicineAntiviral AgentHepatologybusiness.industryGastroenterologyHepatologyHepatitis C Chronicmedicine.diseaseComorbidityHepatitis COrgan transplantHCV; Immunocompromised patients; Organ transplant; Hepatology; GastroenterologyTransplant RecipientsHCV; Immunocompromised patients; Organ transplant; Antiviral Agents; Comorbidity; Hepatitis C Chronic; Humans; Immunocompetence; Italy; Neoplasms; Transplant Recipients; Immunocompromised HostItaly030220 oncology & carcinogenesisHCVHCV Immunocompromised patients Organ transplantPosition paperNeoplasmImmunocompromised patients030211 gastroenterology & hepatologyImmunocompetencebusinessImmunocompetenceDirect actingHumanDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Transfusion-related acute lung injury after intravenous immunoglobulin treatment in a lung transplant recipient

2012

Three weeks after single-lung transplantation for pulmonary fibrosis, a patient with high serum levels of de novo donor-specific antibodies received high-dose intravenous immunoglobulin (IVIG) infusion (scheduled dose: 2 g/kg on 2 days) to prevent antibody-mediated rejection. Within the first hours after completion of infusions, he experienced acute lung injury involving the transplanted lung. Given the clinical evolution and the absence of an alternative diagnosis, transfusion-related acute lung injury (TRALI) was diagnosed. The IVIG administered on each day was from the same batch. At day 110, because of an increase in the serum titers of donor-specific antibodies, IVIG therapy was reintr…

medicine.medical_specialtybiologybusiness.industrymedicine.medical_treatmentHematologyGeneral MedicineLung injurymedicine.diseaseSurgeryTransplantationhemic and lymphatic diseasesAnesthesiaPulmonary fibrosismedicinebiology.proteinLung transplantationLung transplant recipientAntibodybusinessIVIG TherapyTransfusion-related acute lung injuryVox Sanguinis
researchProduct

Assessing the impact on intestinal microbiome and clinical outcomes of antibiotherapy optimisation strategies in haematopoietic stem cell transplant …

2020

GETH (Grupo Español de Trasplante Hematopoyético y Terapia Celular).

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatment1700Antibioticslcsh:MedicinemicrobiomeGraft vs Host DiseaseHematopoietic stem cell transplantationantibioticsAntimicrobial StewardshipFecesInternal medicinegraft versus host diseasemicrobiotamedicineHumansMulticenter Studies as Topic1506infectionsLongitudinal StudiesProspective StudiesAntibiotic prophylaxisbusiness.industryIncidence (epidemiology)lcsh:RHematopoietic Stem Cell TransplantationGeneral MedicineAntibiotic Prophylaxismedicine.diseaseTransplant RecipientsGastrointestinal MicrobiomeTransplantationObservational Studies as Topicsurgical procedures operativeGraft-versus-host diseaseResearch DesignCase-Control StudiesCohortObservational studybusinessHaematology (Incl Blood Transfusion)BMJ Open
researchProduct

T cell–mediated response to SARS‐CoV‐2 in liver transplant recipients with prior COVID‐19

2021

Abstract Whether immunosuppression impairs severe acute respiratory syndrome coronavirus 2‐specific T‐cell‐mediated immunity (SARS‐CoV‐2‐CMI) after liver transplantation (LT) remains unknown. We included 31 LT recipients in whom SARS‐CoV‐2‐CMI was assessed by intracellular cytokine staining (ICS) and interferon (IFN)‐γ FluoroSpot assay after a median of 103 days from COVID‐19 diagnosis. Serum SARS‐CoV‐2 IgG antibodies were measured by ELISA. A control group of non‐transplant immunocompetent patients were matched (1:1 ratio) by age and time from diagnosis. Post‐transplant SARS‐CoV‐2‐CMI was detected by ICS in 90.3% (28/31) of recipients, with higher proportions for IFN‐γ‐producing CD4+ than …

medicine.medical_treatmentT cellT-LymphocytesLiver transplantationAntibodies ViralCOVID-19 TestingAntigenImmunityImmunology and AllergyMedicineHumansPharmacology (medical)Transplantationbiologybusiness.industrySARS-CoV-2COVID-19ImmunosuppressionOriginal ArticlesTransplant RecipientsLiver Transplantationmedicine.anatomical_structureImmunologybiology.proteinOriginal ArticleAntibodybusinessFluoroSpotCD8American Journal of Transplantation
researchProduct

Is COVID‐19 infection more severe in kidney transplant recipients?

2021

International audience; There are no studies which have compared the risk of severe Covid-19 and related mortality between transplant recipients and non-transplant patients. We enrolled two groups of patients hospitalized for Covid-19, i.e., kidney transplant recipients from the French Registry of Solid Organ Transplant (n=306) and a single-center cohort of non-transplant patients (n=795). An analysis was performed among subgroups matched for age and risk factors for severe Covid-19 or mortality. Severe Covid-19 was defined as admission (or transfer) to an intensive care unit, need for mechanical ventilation, or death.Transplant recipients were younger and had more comorbidities compared to…

medicine.medical_treatment[SDV]Life Sciences [q-bio]MESH: Registries*AucunMESH: Comorbidity030230 surgerylaw.inventionchemistry.chemical_compound0302 clinical medicinelawcardiovascular diseaseMESH: Risk Factors[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesclinical research / practiceImmunology and AllergyCumulative incidencePharmacology (medical)kidney transplantation / nephrologyMESH: IncidenceMESH: AgedUnivariate analysisMESH: France / epidemiologyMESH: Middle AgedMESH: Transplant Recipients / statistics & numerical data*Acute kidney injuryIntensive care unit3. Good healthMESH: COVID-19 / epidemiologyCohort[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesglomerular filtration rate (GFR)kidney failure / injurymedicine.medical_specialtyinfection and infectious agents - viralinfectious diseaseBrief CommunicationMESH: Graft Rejection / prevention & control03 medical and health sciencesInternal medicineDiabetes mellitusMESH: Severity of Illness IndexMESH: COVID-19 / diagnosis*medicineHumansMESH: SARS-CoV-2Mechanical ventilationCreatinineTransplantationMESH: Humansbusiness.industrySARS-CoV-2MESH: Graft Rejection / epidemiology*COVID-19MESH: Retrospective Studiesmedicine.diseaseKidney TransplantationTransplant RecipientsMESH: Maleimmunosuppressive regimensMESH: Immunosuppressive Agents / therapeutic useMESH: Pandemics*MESH: Propensity Score*chemistryReinfectionMESH: Immunosuppression / methodsMESH: Intensive Care UnitsbusinessMESH: FemaleMESH: Kidney Transplantation*
researchProduct